Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Graft-versus-host Disease Prevention”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05436418
What this trial is testing

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Who this might be right for
Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell Transplantation
National Cancer Institute (NCI) 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT03983850
What this trial is testing

Optimizing PTCy Dose and Timing

Who this might be right for
Graft Versus Host DiseaseHematologic Neoplasms
National Cancer Institute (NCI) 105
Not applicableNo Longer AvailableNCT01200017
What this trial is testing

Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+9 more
Christopher Dvorak
Early research (Phase 1)Ended earlyNCT04006652
What this trial is testing

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

Who this might be right for
Acute Graft Versus Host DiseaseHaploidentical Hematopoietic Stem Cell Transplant
Washington University School of Medicine 4
Not applicableStudy completedNCT00333190
What this trial is testing

CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

Who this might be right for
Hematologic MalignancyAMLALL+4 more
Dana-Farber Cancer Institute 30
Testing effectiveness (Phase 2)UnknownNCT05914714
What this trial is testing

Ruxolitinib as GVHD Prophylaxis in AA Patients

Who this might be right for
The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Institute of Hematology & Blood Diseases Hospital, China 46
Testing effectiveness (Phase 2)Study completedNCT00823316
What this trial is testing

Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Leukemia
Medipost Co Ltd. 10
Large-scale testing (Phase 3)Ended earlyNCT01749111
What this trial is testing

Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis

Who this might be right for
Acute Myelogenous LeukemiaAcute Lymphoid LeukemiaMyeloproliferative Disease+3 more
Hospital Israelita Albert Einstein 3
Testing effectiveness (Phase 2)Looking for participantsNCT06815003
What this trial is testing

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia+3 more
City of Hope Medical Center 35
Testing effectiveness (Phase 2)Study completedNCT02683525
What this trial is testing

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Graft vs Host DiseaseHematopoietic Stem Cell Transplantation
Sherif S. Farag 37
Testing effectiveness (Phase 2)Study completedNCT04112810
What this trial is testing

Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Who this might be right for
Hematologic Malignancies
Medical College of Wisconsin 51
Early research (Phase 1)Ended earlyNCT03320642
What this trial is testing

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Who this might be right for
Hematologic Malignancies
Incyte Corporation 84
Testing effectiveness (Phase 2)WithdrawnNCT03986086
What this trial is testing

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Hematologic Malignancy
Nelson Chao
Early research (Phase 1)Study completedNCT01700751
What this trial is testing

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Who this might be right for
Leukemia, Acute MyeloidLeukemia, Lymphoblastic,AcuteMyelodysplastic Syndromes
Washington University School of Medicine 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT04395222
What this trial is testing

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Who this might be right for
Hematologic MalignancyBone Marrow Transplant
Weill Medical College of Cornell University 21
Testing effectiveness (Phase 2)Ended earlyNCT02167451
What this trial is testing

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Who this might be right for
Diagnoses That Require Stem Cell TransplantGraft Versus Host Disease (GVHD)
Children's Hospital Medical Center, Cincinnati 31
Testing effectiveness (Phase 2)Ended earlyNCT06271616
What this trial is testing

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Who this might be right for
Chronic Graft Versus Host DiseaseHematopoietic and Lymphatic System Neoplasm
Mayo Clinic 2
Testing effectiveness (Phase 2)Looking for participantsNCT06926595
What this trial is testing

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Who this might be right for
Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation
Milton S. Hershey Medical Center 41
Testing effectiveness (Phase 2)WithdrawnNCT04127721
What this trial is testing

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Who this might be right for
Allogeneic Stem Cell Transplant RecipientHematologic and Lymphocytic DisorderHematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center
Early research (Phase 1)WithdrawnNCT06444022
What this trial is testing

HAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Graft Versus Host Disease
Nanfang Hospital, Southern Medical University
Next Page